Literature DB >> 22156587

Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race.

John Hayes1, Kamyar Kalantar-Zadeh, Jun L Lu, Sharon Turban, John E Anderson, Csaba P Kovesdy.   

Abstract

BACKGROUND/AIMS: Abnormal serum potassium is associated with higher mortality in dialysis patients, but its impact on outcomes in predialysis chronic kidney disease (CKD) is less clear. Furthermore, blacks with normal kidney function have lower urinary potassium excretion, but it is unclear if such differences have a bearing on race-associated outcomes in CKD.
METHODS: We studied predialysis mortality and slopes of estimated glomerular filtration rate, eGFR) associated with serum potassium in 1,227 males with CKD. Mortality was examined in time-dependent Cox models, and slopes of eGFR in linear mixed effects models with adjustments for case mix and laboratory values.
RESULTS: Both hypo- and hyperkalemia were associated with mortality overall and in 933 white patients, but in 294 blacks hypokalemia was a stronger death predictor. Hypokalemia was associated with loss of kidney function independent of race: a 1 mEq/l lower potassium was associated with an adjusted difference in slopes of eGFR of -0.13 ml/min/1.73 m(2)/year (95% CI: -0.20 to -0.07), p < 0.001.
CONCLUSION: Hypo- and hyperkalemia are associated with higher mortality in CKD patients. Blacks appear to better tolerate higher potassium than whites. Hypokalemia is associated with faster CKD progression independent of race. Hyperkalemia management may warrant race-specific consideration, and hypokalemia correction may slow CKD progression. This is a work of the US Government and is not subject to copyright protection in the USA. Foreign copyrights may apply. Published by S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 22156587      PMCID: PMC3267990          DOI: 10.1159/000329511

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  47 in total

1.  Symptoms and course of chronic hypokalemic nephropathy in man.

Authors:  W Cremer; K D Bock
Journal:  Clin Nephrol       Date:  1977-03       Impact factor: 0.975

2.  Cardiovascular and humoral responses to extremes of sodium intake in normal black and white men.

Authors:  F C Luft; L I Rankin; R Bloch; A E Weyman; L R Willis; R H Murray; C E Grim; M H Weinberger
Journal:  Circulation       Date:  1979-09       Impact factor: 29.690

3.  Functional impairment in chronic renal disease. 3. Studies of potassium excretion.

Authors:  H C Gonick; C R Kleeman; M E Rubini; M H Maxwell
Journal:  Am J Med Sci       Date:  1971-05       Impact factor: 2.378

4.  Racial differences in the incidence of treatment for end-stage renal disease.

Authors:  S G Rostand; K A Kirk; E A Rutsky; B A Pate
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

5.  Racial differences in blood pressure in Evans County, Georgia: relationship to sodium and potassium intake and plasma renin activity.

Authors:  C E Grim; F C Luft; J Z Miller; G R Meneely; H D Battarbee; C G Hames; L K Dahl
Journal:  J Chronic Dis       Date:  1980

6.  Racial factors in the incidence and causation of end-stage renal disease (ESRD).

Authors:  R E Easterling
Journal:  Trans Am Soc Artif Intern Organs       Date:  1977

7.  Morphologic aspects of low-potassium and low-sodium nephropathy.

Authors:  T Riemenschneider; A Bohle
Journal:  Clin Nephrol       Date:  1983-06       Impact factor: 0.975

8.  Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages.

Authors:  F C Luft; C E Grim; N Fineberg; M C Weinberger
Journal:  Circulation       Date:  1979-04       Impact factor: 29.690

9.  Relation between ingested potassium and sodium balance in young Blacks and whites.

Authors:  A W Voors; E R Dalferes; G C Frank; G G Aristimuno; G S Berenson
Journal:  Am J Clin Nutr       Date:  1983-04       Impact factor: 7.045

10.  Sodium and potassium status, plasma renin and aldosterone profiles in normotensive and hypertensive Johannesburg blacks.

Authors:  S L Cohen; D Jhetam; J Da Silva; F J Milne; A van der Walt
Journal:  S Afr Med J       Date:  1982-12-11
View more
  56 in total

1.  Mortality and serum sodium in CKD--yet another U‑shaped curve.

Authors:  Anna Jovanovich; Tomas Berl
Journal:  Nat Rev Nephrol       Date:  2012-05       Impact factor: 28.314

Review 2.  Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy.

Authors:  Kamyar Kalantar-Zadeh; Mark Unruh; Philip G Zager; Csaba P Kovesdy; Joanne M Bargman; Jing Chen; Suresh Sankarasubbaiyan; Gaurang Shah; Thomas Golper; Richard A Sherman; David S Goldfarb
Journal:  Am J Kidney Dis       Date:  2014-05-17       Impact factor: 8.860

3.  Serum Potassium, Mortality, and Kidney Outcomes in the Atherosclerosis Risk in Communities Study.

Authors:  Yan Chen; Alex R Chang; Mara A McAdams DeMarco; Lesley A Inker; Kunihiro Matsushita; Shoshana H Ballew; Josef Coresh; Morgan E Grams
Journal:  Mayo Clin Proc       Date:  2016-08-04       Impact factor: 7.616

Review 4.  Updates in hyperkalemia: Outcomes and therapeutic strategies.

Authors:  Csaba P Kovesdy
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

5.  Gene-environment interaction between SCN5A-1103Y and hypokalemia influences QT interval prolongation in African Americans: the Jackson Heart Study.

Authors:  Ermeg L Akylbekova; John P Payne; Christopher Newton-Cheh; Warren L May; Ervin R Fox; James G Wilson; Daniel F Sarpong; Herman A Taylor; Joseph F Maher
Journal:  Am Heart J       Date:  2013-10-22       Impact factor: 4.749

6.  Race, Serum Potassium, and Associations With ESRD and Mortality.

Authors:  Yan Chen; Yingying Sang; Shoshana H Ballew; Adrienne Tin; Alex R Chang; Kunihiro Matsushita; Josef Coresh; Kamyar Kalantar-Zadeh; Miklos Z Molnar; Morgan E Grams
Journal:  Am J Kidney Dis       Date:  2017-03-28       Impact factor: 8.860

7.  Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.

Authors:  Csaba P Kovesdy; Kunihiro Matsushita; Yingying Sang; Nigel J Brunskill; Juan J Carrero; Gabriel Chodick; Takeshi Hasegawa; Hiddo L Heerspink; Atsushi Hirayama; Gijs W D Landman; Adeera Levin; Dorothea Nitsch; David C Wheeler; Josef Coresh; Stein I Hallan; Varda Shalev; Morgan E Grams
Journal:  Eur Heart J       Date:  2018-05-01       Impact factor: 29.983

8.  Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.

Authors:  Laurence Lepage; Anne-Claude Dufour; Jessica Doiron; Katia Handfield; Katherine Desforges; Robert Bell; Michel Vallée; Michel Savoie; Sylvie Perreault; Louis-Philippe Laurin; Vincent Pichette; Jean-Philippe Lafrance
Journal:  Clin J Am Soc Nephrol       Date:  2015-11-17       Impact factor: 8.237

9.  Hypokalemia and hyperkalemia in patients on peritoneal dialysis: incidence and associated factors.

Authors:  Fernanda A Goncalves; Jessica Santos de Jesus; Lilian Cordeiro; Maria Clara T Piraciaba; Luiza K R P de Araujo; Carolina Steller Wagner Martins; Maria Aparecida Dalboni; Benedito J Pereira; Bruno C Silva; Rosa Maria A Moysés; Hugo Abensur; Rosilene M Elias
Journal:  Int Urol Nephrol       Date:  2020-02-03       Impact factor: 2.370

10.  Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease.

Authors:  Georges N Nakhoul; Haiquan Huang; Susana Arrigain; Stacey E Jolly; Jesse D Schold; Joseph V Nally; Sankar D Navaneethan
Journal:  Am J Nephrol       Date:  2015-07-25       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.